# Î±-Synuclein Shares Physical and Functional Homology

Journal of Neuroscience
19, 5782-5791
DOI: 10.1523/jneurosci.19-14-05782.1999

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Maladie de Parkinson Vers un mÃ©canisme de mort neuronale. Journal of Engineering and Technology Management - JET-M, 1997, 14, 25-45. | 1.4 | 65 |
| 2 | Tau and Synuclein and Their Role in Neuropathology. Brain Pathology, 1999, 9, 657-661. | 2.1 | 75 |
| 3 | Synuclein expression is decreased in rat substantia nigra following induction of apoptosis by intrastriatal 6-hydroxydopamine. Neuroscience Letters, 1999, 275, 105-108. | 1.0 | 64 |
| 4 | Î±-Synuclein overexpression promotes aggregation of mutant huntingtin. Biochemical Journal, 2000, 346, 577. | 1.7 | 16 |
| 5 | Î±-Synuclein overexpression promotes aggregation of mutant huntingtin. Biochemical Journal, 2000, 346, 577-581. | 1.7 | 78 |
| 6 | The A53T Î±-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity. Journal of Neuroscience, 2000, 20, 6048-6054. | 1.7 | 504 |
| 8 | Genetic studies in Drosophila. NeuroReport, 2000, 11, R45-R53. | 0.6 | 14 |
| 9 | ?-synuclein is developmentally expressed in cultured rat brain oligodendrocytes. Journal of Neuroscience Research, 2000, 62, 9-14. | 1.3 | 125 |
| 10 | The pathogenesis of multiple system atrophy: Past, present, and future. Movement Disorders, 2000, 15, 784-788. | 2.2 | 23 |
| 11 | Induction of neuronal death by Î±-synuclein. European Journal of Neuroscience, 2000, 12, 3073-3077. | 1.2 | 151 |
| 12 | Neurodegeneration: diseases of the cytoskeleton?. Cell Death and Differentiation, 2000, 7, 861-865. | 5.0 | 88 |
| 13 | A Drosophila model of Parkinson's disease. Nature, 2000, 404, 394-398. | 13.7 | 1,927 |
| 14 | Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature, 2000, 404, 398-402. | 13.7 | 2,197 |
| 15 | Overexpression of human Î±-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Research, 2000, 866, 33-43. | 1.1 | 202 |
| 16 | Alpha-synuclein and Parkinson's disease. Cellular and Molecular Life Sciences, 2000, 57, 1894-1908. | 2.4 | 225 |
| 17 | Subcellular Localization of Wild-Type and Parkinson's Disease-Associated Mutant Î±-Synuclein in Human and Transgenic Mouse Brain. Journal of Neuroscience, 2000, 20, 6365-6373. | 1.7 | 611 |
| 18 | Wild-type but Not Parkinson's Disease-related Ala-53 â†' Thr Mutant Î±-Synuclein Protects Neuronal Cells from Apoptotic Stimuli. Journal of Biological Chemistry, 2000, 275, 24065-24069. | 1.6 | 198 |
| 19 | Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Human Molecular Genetics, 2000, 9, 2683-2689. | 1.4 | 182 |

| # | Article | IF | Citations |
|---|---|---|---|
| 20 | Mechanisms of Neurodegenerative Disorders. Archives of Neurology, 2000, 57, 793. | 4.9 | 76 |
| 21 | Synucleins Are a Novel Class of Substrates for G Protein-coupled Receptor Kinases. Journal of Biological Chemistry, 2000, 275, 26515-26522. | 1.6 | 353 |
| 22 | 14-3-3Î¶ Is an Effector of Tau Protein Phosphorylation. Journal of Biological Chemistry, 2000, 275, 25247-25254. | 1.6 | 197 |
| 23 | Review: Formation and Properties of Amyloid-like Fibrils Derived from Î±-Synuclein and Related Proteins. Journal of Structural Biology, 2000, 130, 300-309. | 1.3 | 93 |
| 24 | Accumulation of Insoluble Î±-Synuclein in Dementia with Lewy Bodies. Neurobiology of Disease, 2000, 7, 192-200. | 2.1 | 75 |
| 25 | Oxidative Stress and Genetics in the Pathogenesis of Parkinson's Disease. Neurobiology of Disease, 2000, 7, 240-250. | 2.1 | 397 |
| 26 | Î±-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress. American Journal of Pathology, 2000, 157, 401-410. | 1.9 | 641 |
| 27 | Enhanced vulnerability to oxidative stress by Î±-synuclein mutations and C-terminal truncation. Neuroscience, 2000, 97, 279-284. | 1.1 | 189 |
| 28 | Mechanisms underlying neural cell death in neurodegenerative diseases: alterations of a developmentally-mediated cellular rheostat. Trends in Neurosciences, 2000, 23, 599-605. | 4.2 | 55 |
| 29 | Mice Lacking Î±-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System. Neuron, 2000, 25, 239-252. | 3.8 | 1,573 |
| 30 | The genetics of Parkinson's disease. Current Opinion in Genetics and Development, 2000, 10, 292-298. | 1.5 | 73 |
| 31 | Chaperone-like activity of synucleins. FEBS Letters, 2000, 474, 116-119. | 1.3 | 196 |
| 32 | Inhibition of Fibrillization and Accumulation of Prefibrillar Oligomers in Mixtures of Human and Mouse Î±-Synuclein. Biochemistry, 2000, 39, 10619-10626. | 1.2 | 226 |
| 33 | Maladie de Parkinson. Annales De L'Institut Pasteur / ActualitÃ©s, 2000, 11, 25-45. | 0.1 | 0 |
| 34 | Prominent Perikaryal Expression of Î±- and Î²-Synuclein in Neurons of Dorsal Root Ganglion and in Medullary Neurons. Experimental Neurology, 2001, 172, 354-362. | 2.0 | 49 |
| 35 | Conformational properties of Î±-synuclein in its free and lipid-associated states 1 1Edited by P. E. Wright. Journal of Molecular Biology, 2001, 307, 1061-1073. | 2.0 | 980 |
| 36 | Reduced Neuritic Outgrowth and Cell Adhesion in Neuronal Cells Transfected with Human Î±-Synuclein. Molecular and Cellular Neurosciences, 2001, 17, 141-150. | 1.0 | 73 |
| 37 | Developmental mechanisms in the pathogenesis of neurodegenerative diseases. Progress in Neurobiology, 2001, 63, 337-363. | 2.8 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 38 | Lack of binding observed between human Î±-synuclein and Bcl-2 protein family. Neuroscience Letters, 2001, 316, 103-107. | 1.0 | 7 |
| 39 | Proteinâ€“protein interactions of alpha-synuclein in brain homogenates and transfected cells. Molecular Brain Research, 2001, 95, 138-145. | 2.5 | 88 |
| 40 | Transfected synphilin-1 forms cytoplasmic inclusions in HEK293 cells. Molecular Brain Research, 2001, 97, 94-102. | 2.5 | 57 |
| 41 | Direct binding and functional coupling of Î±-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB Journal, 2001, 15, 916-926. | 0.2 | 407 |
| 42 | Î²-Synuclein Inhibits Î±-Synuclein Aggregation. Neuron, 2001, 32, 213-223. | 3.8 | 400 |
| 43 | Alpha-synuclein expression is up-regulated in NTera2 cells during neuronal differentiation but unaffected by exposure to cytokines and neurotrophic factors. Parkinsonism and Related Disorders, 2001, 8, 7-17. | 1.1 | 18 |
| 44 | Aggregation and properties of Î±â€'synuclein and related proteins. Spectroscopy, 2001, 15, 141-150. | 0.8 | 2 |
| 45 | Co-association of parkin and Î±-synuclein. NeuroReport, 2001, 12, 2839-2843. | 0.6 | 71 |
| 46 | Expression of ??-synuclein in a human glioma cell line and its up-regulation by interleukin-1??. NeuroReport, 2001, 12, 1909-1912. | 0.6 | 63 |
| 47 | Expression of A53T Mutant But Not Wild-Type Î±-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death. Journal of Neuroscience, 2001, 21, 9549-9560. | 1.7 | 540 |
| 48 | Synuclein-1 is selectively up-regulated in response to nerve growth factor treatment in PC12 cells. Journal of Neurochemistry, 2001, 76, 1165-1176. | 2.1 | 80 |
| 49 | Ubiquitin C-terminal hydrolase-L1 (PGP9.5) expression in human neural cell lines following induction of neuronal differentiation and exposure to cytokines, neurotrophic factors or heat stress. Neuropathology and Applied Neurobiology, 2001, 27, 95-104. | 1.8 | 31 |
| 50 | Self-oligomerization and protein aggregation of Î±-synuclein in the presence of Coomassie Brilliant Blue. FEBS Journal, 2001, 268, 295-301. | 0.2 | 25 |
| 51 | Synucleins in ocular tissues. Journal of Neuroscience Research, 2001, 65, 68-77. | 1.3 | 80 |
| 52 | Glial cell death induced by overexpression of ?-synuclein. Journal of Neuroscience Research, 2001, 65, 432-438. | 1.3 | 87 |
| 53 | Gamma synuclein: Subcellular localization in neuronal and non-neuronal cells and effect on signal transduction. Cytoskeleton, 2001, 49, 218-228. | 4.4 | 55 |
| 54 | Expression of alpha-synuclein in non-apoptotic, slowly degenerating facial motoneurones. Journal of Neurocytology, 2001, 30, 515-521. | 1.6 | 18 |
| 55 | Lewy Body Pathology in Alzheimer's Disease. Journal of Molecular Neuroscience, 2001, 17, 225-232. | 1.1 | 138 |

| # | Article | IF | Citations |
|---|---|---|---|
| 57 | Correction: The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature, 2001, 412, 99-99. | 13.7 | 183 |
| 58 | Alpha synuclein aggregation: is it the toxic gain of function responsible for neurodegeneration in Parkinson's disease?. Mechanisms of Ageing and Development, 2001, 122, 1499-1510. | 2.2 | 57 |
| 59 | Altered expression of the synuclein family mRNA in Lewy body and Alzheimerâ€™s disease. Brain Research, 2001, 914, 48-56. | 1.1 | 150 |
| 60 | Synucleinopathies: a pathological and molecular review. Clinical Neuroscience Research, 2001, 1, 445-455. | 0.8 | 20 |
| 61 | Gene therapeutic approaches to the treatment of Parkinson's disease. Clinical Neuroscience Research, 2001, 1, 483-495. | 0.8 | 7 |
| 62 | The Chaperone Protein 14-3-3Î· Interacts with the Nicotinic Acetylcholine Receptor Î±4 Subunit. Journal of Biological Chemistry, 2001, 276, 28281-28290. | 1.6 | 146 |
| 63 | Ca2+ Binding to Î±-Synuclein Regulates Ligand Binding and Oligomerization. Journal of Biological Chemistry, 2001, 276, 22680-22684. | 1.6 | 134 |
| 64 | Residual Structure and Dynamics in Parkinson's Disease-associated Mutants of Î±-Synuclein. Journal of Biological Chemistry, 2001, 276, 45996-46003. | 1.6 | 233 |
| 65 | Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Human Molecular Genetics, 2001, 10, 919-926. | 1.4 | 442 |
| 66 | Accumulation of Mutant Huntingtin Fragments in Aggresome-like Inclusion Bodies as a Result of Insufficient Protein Degradation. Molecular Biology of the Cell, 2001, 12, 1393-1407. | 0.9 | 583 |
| 67 | Î±-Synuclein Affects the MAPK Pathway and Accelerates Cell Death. Journal of Biological Chemistry, 2001, 276, 45320-45329. | 1.6 | 131 |
| 68 | Lipid Droplet Binding and Oligomerization Properties of the Parkinson's Disease Protein Î±-Synuclein. Journal of Biological Chemistry, 2002, 277, 6344-6352. | 1.6 | 396 |
| 69 | Î³-Synuclein Promotes Cancer Cell Survival and Inhibits Stress- and Chemotherapy Drug-induced Apoptosis by Modulating MAPK Pathways. Journal of Biological Chemistry, 2002, 277, 35050-35060. | 1.6 | 108 |
| 70 | Î±â€Synuclein regulates neuronal survival via Bclâ€2 family expression and PI3/Akt kinase pathway. FASEB Journal, 2002, 16, 1-20. | 0.2 | 198 |
| 72 | 14-3-3 Proteins in Lewy Bodies in Parkinson Disease and Diffuse Lewy Body Disease Brains. Journal of Neuropathology and Experimental Neurology, 2002, 61, 245-253. | 0.9 | 145 |
| 73 | Distinct Roles of the N-terminal-binding Domain and the C-terminal-solubilizing Domain of Î±-Synuclein, a Molecular Chaperone. Journal of Biological Chemistry, 2002, 277, 28512-28520. | 1.6 | 101 |
| 74 | Golgi Fragmentation Occurs in the Cells with Prefibrillar Î±-Synuclein Aggregates and Precedes the Formation of Fibrillar Inclusion. Journal of Biological Chemistry, 2002, 277, 48984-48992. | 1.6 | 249 |
| 75 | Î±-Synuclein Interacts with Phospholipase D Isozymes and Inhibits Pervanadate-induced Phospholipase D Activation in Human Embryonic Kidney-293 Cells. Journal of Biological Chemistry, 2002, 277, 12334-12342. | 1.6 | 118 |

| # | Article | IF | Citations |
|---|---|---|---|
| 76 | Evidence that Î±-synuclein functions as a negative regulator of Ca++-dependent Î±-granule release from human platelets. Blood, 2002, 100, 2506-2514. | 0.6 | 51 |
| 77 | Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of Î±-Synuclein in the Nigrostriatal System. Journal of Neuroscience, 2002, 22, 2780-2791. | 1.7 | 633 |
| 78 | A Role for Î±-Synuclein in the Regulation of Dopamine Biosynthesis. Journal of Neuroscience, 2002, 22, 3090-3099. | 1.7 | 588 |
| 79 | Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Human Molecular Genetics, 2002, 11, 2395-2407. | 1.4 | 226 |
| 80 | Cytoplasmic Aggregates of Phosphorylated Extracellular Signal-Regulated Protein Kinases in Lewy Body Diseases. American Journal of Pathology, 2002, 161, 2087-2098. | 1.9 | 139 |
| 81 | Pharmacogenomics of Neurodegenerative Diseases: Examples and Perspectives. , 0, , 347-367. | | 0 |
| 82 | Activation of Pyk2/RAFTK induces tyrosine phosphorylation of Î±-synuclein via Src-family kinases. FEBS Letters, 2002, 521, 190-194. | 1.3 | 35 |
| 83 | Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity?. Parkinsonism and Related Disorders, 2002, 8, 389-393. | 1.1 | 97 |
| 84 | 14-3-3 protein is a component of Lewy bodies in Parkinsonâ€™s diseaseâ€”Mutation analysis and association studies of 14-3-3 eta. Molecular Brain Research, 2002, 108, 33-39. | 2.5 | 53 |
| 85 | Parkinsonâ€™s Genetics: Molecular Insights for the New Millennium. NeuroToxicology, 2002, 23, 503-514. | 1.4 | 19 |
| 86 | Human Î±-Synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neuroscience Letters, 2002, 320, 146-150. | 1.0 | 229 |
| 87 | Amyloid Precursor Protein, Presenilins, and alpha -Synuclein: Molecular Pathogenesis and Pharmacological Applications in Alzheimer's Disease. Pharmacological Reviews, 2002, 54, 469-525. | 7.1 | 421 |
| 89 | Overexpression of human Î±-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Research, 2002, 926, 42-50. | 1.1 | 132 |
| 90 | MPP+ increases Î±-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Research, 2002, 935, 32-39. | 1.1 | 132 |
| 91 | Immunohistochemical comparison of Î±- and Î²-synuclein in adult rat central nervous system. Brain Research, 2002, 941, 118-126. | 1.1 | 75 |
| 92 | Upregulation of alpha-synuclein by lipopolysaccharide and interleukin-1 in human macrophages. Pathology International, 2002, 52, 572-577. | 0.6 | 52 |
| 93 | Accumulation of 14-3-3 proteins in glial cytoplasmic inclusions in multiple system atrophy. Annals of Neurology, 2002, 52, 722-731. | 2.8 | 53 |
| 94 | Synucleins in glaucoma: Implication of ?-synuclein in glaucomatous alterations in the optic nerve. Journal of Neuroscience Research, 2002, 68, 97-106. | 1.3 | 75 |

| # | Article | IF | Citations |
|---|---|---|---|
| 95 | Long-term culture of mouse cortical neurons as a model for neuronal development, aging, and death. Journal of Neurobiology, 2002, 51, 9-23. | 3.7 | 234 |
| 96 | Age-dependent differential regulation of genes encoding APP and Î±-synuclein in hippocampal synaptic plasticity. Hippocampus, 2002, 12, 55-62. | 0.9 | 21 |
| 97 | Increased Expression of Rat Synuclein in the Substantia Nigra Pars Compacta Identified by mRNA Differential Display in a Model of Developmental Target Injury. Journal of Neurochemistry, 2002, 73, 2586-2599. | 2.1 | 119 |
| 98 | Immature and Mature Cortical Neurons Engage Different Apoptotic Mechanisms Involving Caspase-3 and the Mitogen-Activated Protein Kinase Pathway. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 935-950. | 2.4 | 80 |
| 99 | Releasing the nerve cell killers. Nature Medicine, 2002, 8, 564-565. | 15.2 | 7 |
| 100 | Dopamine-dependent neurotoxicity of Î±-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. Nature Medicine, 2002, 8, 600-606. | 15.2 | 682 |
| 101 | Functional specificity in 14-3-3 isoform interactions through dimer formation and phosphorylation. Chromosome location of mammalian isoforms and variants. Plant Molecular Biology, 2002, 50, 993-1010. | 2.0 | 148 |
| 102 | Mutant and Wild-Type Î±-Synuclein Interact with Mitochondrial Cytochrome C Oxidase. Journal of Molecular Neuroscience, 2002, 18, 229-238. | 1.1 | 99 |
| 103 | The Cell Biology of Î± Synuclein. NeuroMolecular Medicine, 2002, 1, 95-110. | 1.8 | 28 |
| 104 | Î±-Synuclein: Its Biological Function and Role in Neurodegenerative Diseases. Journal of Molecular Neuroscience, 2003, 20, 83-92. | 1.1 | 50 |
| 105 | Role of Protein Aggregation in Mitochondrial Dysfunction and Neurodegeneration in Alzheimer's and Parkinson's Diseases. NeuroMolecular Medicine, 2003, 4, 21-36. | 1.8 | 410 |
| 106 | Cycles of aberrant synaptic sprouting and neurodegeneration in Alzheimer's and dementia with Lewy bodies. Neurochemical Research, 2003, 28, 1743-1756. | 1.6 | 73 |
| 107 | Immunoexpression of 14-3-3 proteins in glial cytoplasmic inclusions of multiple system atrophy. Acta Neuropathologica, 2003, 106, 66-70. | 3.9 | 21 |
| 108 | Tau and 14-3-3 in glial cytoplasmic inclusions of multiple system atrophy. Acta Neuropathologica, 2003, 106, 243-250. | 3.9 | 36 |
| 110 | Î±-Synuclein expression localizes to the Golgi apparatus in bovine adrenal medullary chromaffin cells. Brain Research, 2003, 984, 233-236. | 1.1 | 16 |
| 111 | Tumor necrosis factor-?-induced cell death in U373 cells overexpressing ?-synuclein. Journal of Neuroscience Research, 2003, 73, 334-340. | 1.3 | 37 |
| 112 | Regulation of Î±-synuclein by bFGF in cultured ventral midbrain dopaminergic neurons. Journal of Neurochemistry, 2003, 84, 803-813. | 2.1 | 39 |
| 113 | Molecular changes in fetal Down syndrome brain. Journal of Neurochemistry, 2003, 84, 895-904. | 2.1 | 87 |

| # | Article | IF | Citations |
|---|---|---|---|
| 114 | Î±-Synuclein up-regulates expression of caveolin-1 and down-regulates extracellular signal-regulated kinase activity in B103 neuroblastoma cells: role in the pathogenesis of Parkinson's disease. Journal of Neurochemistry, 2003, 85, 1468-1479. | 2.1 | 85 |
| 115 | 14-3-3 proteins in the nervous system. Nature Reviews Neuroscience, 2003, 4, 752-762. | 4.9 | 405 |
| 116 | Challenges and complexities of Î±-synuclein toxicity: new postulates in unfolding the mystery associated with Parkinsonâ€™s disease. Archives of Biochemistry and Biophysics, 2003, 418, 169-178. | 1.4 | 33 |
| 117 | A Structural and Functional Role for 11-mer Repeats in Î±-Synuclein and Other Exchangeable Lipid Binding Proteins. Journal of Molecular Biology, 2003, 329, 763-778. | 2.0 | 404 |
| 118 | Interaction of Akt-Phosphorylated Ataxin-1 with 14-3-3 Mediates Neurodegeneration in Spinocerebellar Ataxia Type 1. Cell, 2003, 113, 457-468. | 13.5 | 402 |
| 119 | Part II: Î±-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology, 2003, 45, 14-44. | 2.0 | 254 |
| 120 | Cell cycle aberrations by Î±-synuclein over-expression and cyclin B immunoreactivity in Lewy bodies. Neurobiology of Aging, 2003, 24, 687-696. | 1.5 | 72 |
| 121 | Heat shock proteins reduce aggregation and facilitate degradation of tau protein. International Congress Series, 2003, 1252, 383-393. | 0.2 | 6 |
| 122 | Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease. Trends in Molecular Medicine, 2003, 9, 126-132. | 3.5 | 131 |
| 123 | Î±-Synuclein Aggregation: A Link Between Mitochondrial Defects and Parkinson's Disease?. Antioxidants and Redox Signaling, 2003, 5, 337-348. | 2.5 | 43 |
| 124 | Nigrostriatal Â-synucleinopathy induced by viral vector-mediated overexpression of human Â-synuclein: A new primate model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2884-2889. | 3.3 | 382 |
| 125 | Neurons Expressing the Highest Levels of Î³-Synuclein Are Unaffected by Targeted Inactivation of the Gene. Molecular and Cellular Biology, 2003, 23, 8233-8245. | 1.1 | 65 |
| 126 | Aggregated and Monomeric Î±-Synuclein Bind to the S6â€² Proteasomal Protein and Inhibit Proteasomal Function. Journal of Biological Chemistry, 2003, 278, 11753-11759. | 1.6 | 364 |
| 127 | Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Human Molecular Genetics, 2003, 12, 2625-2635. | 1.4 | 133 |
| 128 | Chaperones increase association of tau protein with microtubules. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 721-726. | 3.3 | 421 |
| 129 | Parkinson's Disease-associated Î±-Synuclein Is a Calmodulin Substrate. Journal of Biological Chemistry, 2003, 278, 17379-17387. | 1.6 | 82 |
| 130 | Recent Advances on α-Synuclein Cell Biology: Functions and Dysfunctions. Current Molecular Medicine, 2003, 3, 17-24. | 0.6 | 20 |
| 131 | Î±-Synuclein aggregation and neurodegenerative diseases. Journal of Alzheimer's Disease, 2003, 5, 139-148. | 1.2 | 66 |

| # | Article | IF | Citations |
|---|---|---|---|
| 133 | PARK1 and Î±-Synuclein. , 2003, , 287-304. | | 0 |
| 134 | Molecular Mechanisms of Neurodegenerative Disorders. , 0, , 377-409. | | 1 |
| 135 | Stem Cells in the Adult Brain. , 2004, , 219-224. | | 2 |
| 137 | Unlocking the code of 14-3-3. Journal of Cell Science, 2004, 117, 1875-1884. | 1.2 | 437 |
| 138 | Î±-Synuclein Is Required for the Fibrillar Nature of Ubiquitinated Inclusions Induced by Proteasomal Inhibition in Primary Neurons. Journal of Biological Chemistry, 2004, 279, 46915-46920. | 1.6 | 45 |
| 139 | Î²-Synuclein Regulates Akt Activity in Neuronal Cells. Journal of Biological Chemistry, 2004, 279, 23622-23629. | 1.6 | 93 |
| 140 | Degradative organelles containing mislocalized Î±- and Î²-synuclein proliferate in presenilin-1 null neurons. Journal of Cell Biology, 2004, 165, 335-346. | 2.3 | 108 |
| 141 | Î±â€Synuclein induces apoptosis by altered expression in human peripheral lymphocytes in Parkinsonâ€™s disease. FASEB Journal, 2004, 18, 1615-1617. | 0.2 | 81 |
| 142 | Protective effect of TATâ€delivered Î±â€synuclein: relevance of the Câ€terminal domain and involvement of HSP70. FASEB Journal, 2004, 18, 1713-1715. | 0.2 | 77 |
| 143 | Analysis of Î±-Synuclein-associated Proteins by Quantitative Proteomics. Journal of Biological Chemistry, 2004, 279, 39155-39164. | 1.6 | 149 |
| 144 | MAP2 prevents protein aggregation and facilitates reactivation of unfolded enzymes. Implications for the chaperone-like activity of MAP2. FEBS Journal, 2004, 271, 1488-1496. | 0.2 | 16 |
| 145 | Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice. Journal of Neurochemistry, 2004, 89, 1126-1136. | 2.1 | 135 |
| 146 | Could a loss of Î±â€synuclein function put dopaminergic neurons at risk?. Journal of Neurochemistry, 2004, 89, 1318-1324. | 2.1 | 130 |
| 147 | Lack of alpha-synuclein does not alter apoptosis of neonatal catecholaminergic neurons. European Journal of Neuroscience, 2004, 20, 1969-1972. | 1.2 | 29 |
| 148 | Annular alpha-synuclein species from purified multiple system atrophy inclusions. Journal of Neurochemistry, 2004, 90, 502-512. | 2.1 | 70 |
| 149 | Pathological Proteins in Parkinson's Disease: Focus on the Proteasome. Journal of Molecular Neuroscience, 2004, 24, 425-442. | 1.1 | 50 |
| 150 | Neurobiology of Î±-Synuclein. Molecular Neurobiology, 2004, 30, 001-022. | 1.9 | 95 |
| 151 | The Role of Â-Synuclein in Both Neuroprotection and Neurodegeneration. Annals of the New York Academy of Sciences, 2004, 1035, 250-270. | 1.8 | 89 |

| # | Article | IF | Citations |
|---|---|---|---|
| 152 | Synucleins and their relationship to Parkinsonâ€™s disease. Cell and Tissue Research, 2004, 318, 163-174. | 1.5 | 33 |
| 153 | 14-3-3 proteins in Lewy body-like hyaline inclusions in patients with sporadic amyotrophic lateral sclerosis. Acta Neuropathologica, 2004, 108, 531-537. | 3.9 | 21 |
| 154 | Î±-Synuclein exhibits competitive interaction between calmodulin and synthetic membranes. Journal of Neurochemistry, 2004, 82, 1007-1017. | 2.1 | 57 |
| 155 | Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human Î±-synuclein. Journal of Neurochemistry, 2004, 86, 165-172. | 2.1 | 328 |
| 156 | Î±-Synuclein protects naive but not dbcAMP-treated dopaminergic cell types from 1-methyl-4-phenylpyridinium toxicity. Journal of Neurochemistry, 2004, 86, 196-209. | 2.1 | 39 |
| 157 | 1-Benzyl-1,2,3,4-tetrahydroisoquinoline, a Parkinsonism-inducing endogenous toxin, increases ?-synuclein expression and causes nuclear damage in human dopaminergic cells. Journal of Neuroscience Research, 2004, 76, 563-571. | 1.3 | 35 |
| 158 | Alteration in Î±-synuclein mRNA expression in Parkinson's disease. Movement Disorders, 2004, 19, 162-170. | 2.2 | 111 |
| 159 | Inhibition of Hsp90: a new strategy for inhibiting protein kinases. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2004, 1697, 233-242. | 1.1 | 130 |
| 160 | Does Î±â€synuclein modulate dopaminergic synaptic content and tone at the synapse?. FASEB Journal, 2004, 18, 637-647. | 0.2 | 157 |
| 161 | Trypsin Disrupts the Trafficking of the Human Dopamine Transporter by Î±-Synuclein and Its A30P Mutantâ€. Biochemistry, 2004, 43, 1242-1253. | 1.2 | 39 |
| 162 | Double-knockout mice for Â- and Â-synucleins: Effect on synaptic functions. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14966-14971. | 3.3 | 392 |
| 163 | Neurodegenerative diseases caused by protein aggregation: a phenomenon at the borderline between molecular evolution and ageing. Pharmacological Research, 2004, 50, 419-431. | 3.1 | 18 |
| 164 | Genetic contributions to Parkinson's disease. Brain Research Reviews, 2004, 46, 44-70. | 9.1 | 83 |
| 165 | Following the leader: fibrillization of ?-synuclein and tau. Experimental Neurology, 2004, 187, 235-239. | 2.0 | 13 |
| 166 | Î±-Synuclein has structural and functional similarities to small heat shock proteins. Biochemical and Biophysical Research Communications, 2004, 324, 1352-1359. | 1.0 | 41 |
| 167 | Î±-Synuclein, Parkinson's disease, and Alzheimer's disease. Parkinsonism and Related Disorders, 2004, 10, S9-S13. | 1.1 | 58 |
| 168 | Genes, proteins, and neurotoxins involved in Parkinsonâ€™s disease. Progress in Neurobiology, 2004, 73, 151-177. | 2.8 | 162 |
| 169 | The 14-3-3 Protein Îµ Isoform Expressed in Reactive Astrocytes in Demyelinating Lesions of Multiple Sclerosis Binds to Vimentin and Glial Fibrillary Acidic Protein in Cultured Human Astrocytes. American Journal of Pathology, 2004, 165, 577-592. | 1.9 | 66 |

| # | Article | IF | Citations |
|---|---|---|---|
| 170 | Alpha-synuclein and transgenic mouse models. Neurobiology of Disease, 2004, 17, 123-130. | 2.1 | 187 |
| 171 | Zeta 14-3-3 protein favours the formation of human tau fibrillar polymers. Neuroscience Letters, 2004, 357, 143-146. | 1.0 | 64 |
| 172 | Interaction of the Molecular Chaperone Î±B-Crystallin with Î±-Synuclein: Effects on Amyloid Fibril Formation and Chaperone Activity. Journal of Molecular Biology, 2004, 340, 1167-1183. | 2.0 | 198 |
| 173 | Î±â€Synuclein and Parkinson's disease. FASEB Journal, 2004, 18, 617-626. | 0.2 | 262 |
| 174 | Î±-Synuclein: Normal Function and Role in Neurodegenerative Diseases. Current Topics in Developmental Biology, 2004, 60, 17-54. | 1.0 | 177 |
| 175 | Functional Interactions of Tau and their Relevance for Alzheimers Disease. Current Alzheimer Research, 2004, 1, 255-269. | 0.7 | 44 |
| 177 | The 14-3-3 Protein Forms a Molecular Complex with Heat Shock Protein Hsp60 and Cellular Prion Protein. Journal of Neuropathology and Experimental Neurology, 2005, 64, 858-868. | 0.9 | 57 |
| 178 | Î±-Synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy. Biochemical Society Transactions, 2005, 33, 1106-1110. | 1.6 | 36 |
| 179 | Î±-Synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy. Biochemical Society Transactions, 2005, 33, 1106. | 1.6 | 47 |
| 180 | Peripheral Sensory Neurons Survive in the Absence of Î±- and Î³-Synucleins. Journal of Molecular Neuroscience, 2005, 25, 157-164. | 1.1 | 17 |
| 181 | Î±-Synuclein and Dopamine Metabolism. Molecular Neurobiology, 2005, 31, 243-254. | 1.9 | 66 |
| 182 | Heat Shock Protein 90 Indirectly Regulates ERK Activity by Affecting Raf Protein Metabolism. Acta Biochimica Et Biophysica Sinica, 2005, 37, 501-505. | 0.9 | 43 |
| 183 | The role of Î±-synuclein in neurodegenerative diseases. , 2005, 105, 311-331. | | 172 |
| 184 | Lysosomal pathology associated with ?-synuclein accumulation in transgenic models using an eGFP fusion protein. Journal of Neuroscience Research, 2005, 80, 247-259. | 1.3 | 77 |
| 185 | Alpha-synuclein dysfunction in Lewy body diseases. Movement Disorders, 2005, 20, S37-S44. | 2.2 | 76 |
| 186 | Pathophysiology: biochemistry of Parkinson's disease. , 2005, , 598-611. | | 0 |
| 188 | Clinical Spectrum and Pathological Features of Multiple System Atrophy. , 2005, , 541-570. | | 2 |
| 189 | Multiple system atrophy. , 2005, , 623-662. | | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 190 | Glycogen Synthase Kinase 3Î² Modulates Synphilin-1 Ubiquitylation and Cellular Inclusion Formation by SIAH. Journal of Biological Chemistry, 2005, 280, 42877-42886. | 1.6 | 41 |
| 191 | Proteomics of the Injured Rat Sciatic Nerve Reveals Protein Expression Dynamics During Regeneration. Molecular and Cellular Proteomics, 2005, 4, 120-132. | 2.5 | 60 |
| 192 | Molecular Anhydrobiology: Identifying Molecules Implicated in Invertebrate Anhydrobiosis. Integrative and Comparative Biology, 2005, 45, 702-709. | 0.9 | 88 |
| 193 | Î±-Synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. Journal of Cell Science, 2005, 118, 3523-3530. | 1.2 | 219 |
| 194 | The Co-chaperone Carboxyl Terminus of Hsp70-interacting Protein (CHIP) Mediates Î±-Synuclein Degradation Decisions between Proteasomal and Lysosomal Pathways. Journal of Biological Chemistry, 2005, 280, 23727-23734. | 1.6 | 298 |
| 195 | Similar Patterns of Mitochondrial Vulnerability and Rescue Induced by Genetic Modification of Î±-Synuclein, Parkin, and DJ-1 in Caenorhabditis elegans*. Journal of Biological Chemistry, 2005, 280, 42655-42668. | 1.6 | 223 |
| 196 | 14-3-3 Proteins: A Number of Functions for a Numbered Protein. Science Signaling, 2005, 2005, re10-re10. | 1.6 | 228 |
| 197 | Regulation of Î±-Synuclein Expression by Poly (ADP Ribose) Polymerase-1 (PARP-1) Binding to the NACP-Rep1 Polymorphic Site Upstream of the SNCA Gene. American Journal of Human Genetics, 2005, 76, 478-492. | 2.6 | 90 |
| 198 | Fluorescence Studies Suggest a Role for Î±-Synuclein in the Phosphatidylinositol Lipid Signaling Pathway. Biochemistry, 2005, 44, 462-470. | 1.2 | 55 |
| 199 | Wild-type Î±-synuclein interacts with pro-apoptotic proteins PKCÎ´ and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death. Molecular Brain Research, 2005, 139, 137-152. | 2.5 | 65 |
| 200 | Gene dosage and pathogenesis of Parkinson's disease. Trends in Molecular Medicine, 2005, 11, 91-96. | 3.5 | 95 |
| 201 | Influence of maternal alcohol administration on c-Fos expression in the hippocampus of infant rats. Neuroscience Letters, 2005, 378, 44-48. | 1.0 | 12 |
| 202 | Tau phosphorylation increases in symptomatic mice overexpressing A30P Î±-synuclein. Experimental Neurology, 2005, 192, 274-287. | 2.0 | 96 |
| 203 | Temporal evolution of mouse striatal gene expression following MPTP injury. Neurobiology of Aging, 2005, 26, 765-775. | 1.5 | 16 |
| 204 | Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Human Molecular Genetics, 2005, 14, 3801-3811. | 1.4 | 321 |
| 205 | Identification of human Î±-synuclein specific single chain antibodies. Biochemical and Biophysical Research Communications, 2006, 349, 1198-1205. | 1.0 | 30 |
| 206 | Î±-Synuclein protects SH-SY5Y cells from dopamine toxicity. Biochemical and Biophysical Research Communications, 2006, 349, 1294-1300. | 1.0 | 33 |
| 207 | Involvement of RHO GTPases and ERK in synuclein-Î³ enhanced cancer cell motility. International Journal of Oncology, 2006, 29, 1201. | 1.4 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 210 | Attenuation of the norepinephrine transporter activity and trafficking via interactions with Î±-synuclein. European Journal of Neuroscience, 2006, 24, 3141-3152. | 1.2 | 53 |
| 211 | Chaperone and anti-chaperone: Two-faced synuclein as stimulator of synaptic evolution. Neuropathology, 2006, 26, 383-392. | 0.7 | 20 |
| 212 | Oxidative Modifications of Î±â€Synuclein. Annals of the New York Academy of Sciences, 2003, 991, 93-100. | 1.8 | 75 |
| 213 | Localization of Phosphorylated ERK/MAP Kinases to Mitochondria and Autophagosomes in Lewy Body Diseases. Brain Pathology, 2003, 13, 473-481. | 2.1 | 218 |
| 214 | Substrate-mediated enhancement of phosphorylated tyrosine hydroxylase in nigrostriatal dopamine neurons: evidence for a role of alpha-synuclein. Journal of Neurochemistry, 2006, 96, 950-959. | 2.1 | 12 |
| 215 | Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells. Journal of Neurochemistry, 2006, 99, 1188-1196. | 2.1 | 93 |
| 216 | Î±-Synuclein gene ablation increases docosahexaenoic acid incorporation and turnover in brain phospholipids. Journal of Neurochemistry, 2006, 101, 201-211. | 2.1 | 72 |
| 217 | Physiology and Pathophysiology of Î±â€Synuclein: Cell Culture and Transgenic Animal Models Based on a Parkinson's Diseaseâ€associated Protein. Annals of the New York Academy of Sciences, 2000, 920, 33-41. | 1.8 | 98 |
| 218 | 14-3-3Î· is a novel regulator of parkin ubiquitin ligase. EMBO Journal, 2006, 25, 211-221. | 3.5 | 107 |
| 219 | Î±-Synuclein Budding Yeast Model: Toxicity Enhanced by Impaired Proteasome and Oxidative Stress. Journal of Molecular Neuroscience, 2006, 28, 161-178. | 1.1 | 63 |
| 220 | Levels of mRNA Coding for Î±-, Î²-, and Î³-Synuclein in the Brains of Newborn, Juvenile, and Adult Rats. Journal of Molecular Neuroscience, 2006, 29, 269-278. | 1.1 | 12 |
| 221 | Î±-Synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathologica, 2006, 112, 237-251. | 3.9 | 179 |
| 222 | Î±-Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice. Acta Neuropathologica, 2006, 112, 681-689. | 3.9 | 30 |
| 223 | Inhibitors of Î±-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinsonâ€™s disease and related disorders. Experimental Brain Research, 2006, 173, 223-233. | 0.7 | 59 |
| 224 | The neurotoxin, MPP+, induces hyperphosphorylation ofTau, in the presence of Î±-Synuclein, in SH-SY5Y neuroblastoma cells. Neurotoxicity Research, 2006, 10, 1-10. | 1.3 | 46 |
| 225 | 14-3-3 proteins: A historic overview. Seminars in Cancer Biology, 2006, 16, 162-172. | 4.3 | 716 |
| 226 | Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. Neurobiology of Disease, 2006, 23, 522-532. | 2.1 | 89 |
| 227 | Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. Movement Disorders, 2006, 21, 1703-1708. | 2.2 | 139 |

| # | Article | IF | Citations |
|---|---|---|---|
| 228 | Functional Repression of cAMP Response Element in 6-Hydroxydopamine-treated Neuronal Cells. Journal of Biological Chemistry, 2006, 281, 17870-17881. | 1.6 | 96 |
| 229 | Endogenous Â-Synuclein Is Induced by Valproic Acid through Histone Deacetylase Inhibition and Participates in Neuroprotection against Glutamate-Induced Excitotoxicity. Journal of Neuroscience, 2006, 26, 7502-7512. | 1.7 | 176 |
| 230 | Cytosolic Catechols Inhibit Â-Synuclein Aggregation and Facilitate the Formation of Intracellular Soluble Oligomeric Intermediates. Journal of Neuroscience, 2006, 26, 10068-10078. | 1.7 | 135 |
| 233 | Is Alpha-Synuclein Pathology a Target for Treatment of Neurodegenerative Disorders?. Current Alzheimer Research, 2007, 4, 556-561. | 0.7 | 6 |
| 234 | Protein Kinase CÂ Negatively Regulates Tyrosine Hydroxylase Activity and Dopamine Synthesis by Enhancing Protein Phosphatase-2A Activity in Dopaminergic Neurons. Journal of Neuroscience, 2007, 27, 5349-5362. | 1.7 | 92 |
| 235 | Is alpha-Synuclein Pathology a Target for Treatment of Neurodegenerative Disorders?. Current Alzheimer Research, 2007, 4, 446-457. | 0.7 | 6 |
| 236 | Parkinsons Disease: Genetics and Beyond. Current Neuropharmacology, 2007, 5, 99-113. | 1.4 | 28 |
| 237 | Î±-Synuclein Stimulates Differentiation of Osteosarcoma Cells. Journal of Biological Chemistry, 2007, 282, 5736-5748. | 1.6 | 32 |
| 238 | Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage. Human Molecular Genetics, 2007, 16, 2377-2393. | 1.4 | 162 |
| 239 | Protection against Î²-Amyloid-induced Apoptosis by Peptides Interacting with Î²-Amyloid. Journal of Biological Chemistry, 2007, 282, 31238-31249. | 1.6 | 40 |
| 240 | Parkinson's disease genetic mutations increase cell susceptibility to stress: Mutant Î±-synuclein enhances H2O2- and Sin-1-induced cell death. Neurobiology of Aging, 2007, 28, 1709-1717. | 1.5 | 53 |
| 241 | RNAi of 14-3-3Î· protein increases intracellular stability of tyrosine hydroxylase. Biochemical and Biophysical Research Communications, 2007, 363, 817-821. | 1.0 | 11 |
| 242 | Anti-fibrillogenic and fibril-destabilizing activity of nicotine in vitro: Implications for the prevention and therapeutics of Lewy body diseases. Experimental Neurology, 2007, 205, 414-424. | 2.0 | 29 |
| 243 | Microarray analysis of oxidative stress regulated genes in mesencephalic dopaminergic neuronal cells: Relevance to oxidative damage in Parkinson's disease. Neurochemistry International, 2007, 50, 834-847. | 1.9 | 61 |
| 244 | Î±-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton. Neurobiology of Disease, 2007, 26, 521-531. | 2.1 | 109 |
| 246 | Aggregated Â-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo. Journal of Neuroscience, 2007, 27, 3338-3346. | 1.7 | 271 |
| 247 | Î³â€Synuclein and the progression of cancer. FASEB Journal, 2007, 21, 3419-3430. | 0.2 | 94 |
| 248 | GM1 Specifically Interacts with Î±-Synuclein and Inhibits Fibrillation. Biochemistry, 2007, 46, 1868-1877. | 1.2 | 239 |

| # | Article | IF | Citations |
|---|---|---|---|
| 249 | 14-3-3 Expression in Denervated Hippocampus after Entorhinal Cortex Lesion Assessed by Culture-Derived Isotope Tags in Quantitative Proteomics. Journal of Proteome Research, 2007, 6, 3491-3500. | 1.8 | 9 |
| 250 | The commonality of protein interaction networks determined in neurodegenerative disorders (NDDs). Bioinformatics, 2007, 23, 2129-2138. | 1.8 | 52 |
| 251 | Protein Aggregation Disorders. , 2007, , 111-123. | | 2 |
| 252 | The proteomic approach in Parkinson's disease. Proteomics - Clinical Applications, 2007, 1, 1428-1435. | 0.8 | 9 |
| 253 | Alphaâ€synuclein protects cerebellar granule neurons against 6â€hydroxydopamineâ€induced death. Journal of Neurochemistry, 2007, 103, 518-530. | 2.1 | 49 |
| 254 | Functional protein kinase arrays reveal inhibition of pâ€21â€activated kinase 4 by Î±â€synuclein oligomers. Journal of Neurochemistry, 2007, 103, 2401-2407. | 2.1 | 18 |
| 255 | Physiological and pathological properties of Î±-synuclein. Cellular and Molecular Life Sciences, 2007, 64, 2194-2201. | 2.4 | 112 |
| 256 | Whole genome expression analyses of single- and double-knock-out mice implicate partially overlapping functions of alpha- and gamma-synuclein. Neurogenetics, 2007, 8, 71-81. | 0.7 | 30 |
| 257 | Overexpressed Alpha-Synuclein Regulated the Nuclear Factor-kappaB Signal Pathway. Cellular and Molecular Neurobiology, 2008, 28, 21-33. | 1.7 | 43 |
| 258 | Inhibition of Vesicular Monoamine Transporter-2 Activity in Î±-Synuclein Stably Transfected SH-SY5Y Cells. Cellular and Molecular Neurobiology, 2008, 28, 35-47. | 1.7 | 73 |
| 259 | Silencing Î±-Synuclein Gene Expression Enhances Tyrosine Hydroxylase Activity in MN9D Cells. Neurochemical Research, 2008, 33, 1401-1409. | 1.6 | 48 |
| 260 | Mitochondrial association of alpha-synuclein causes oxidative stress. Cellular and Molecular Life Sciences, 2008, 65, 1272-1284. | 2.4 | 289 |
| 261 | RNA interference mediated silencing of Î±-synuclein in MN9D cells and its effects on cell viability. Neuroscience Bulletin, 2008, 24, 96-104. | 1.5 | 9 |
| 262 | Sensitization of Neuronal Cells to Oxidative Stress with Mutated Human Î±-Synuclein. Journal of Neurochemistry, 2008, 75, 2546-2554. | 2.1 | 83 |
| 263 | The solubility of Î±-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. Journal of Neurochemistry, 2008, 76, 87-96. | 2.1 | 196 |
| 264 | Microglial phagocytosis is enhanced by monomeric Î±â€synuclein, not aggregated Î±â€synuclein: Implications for Parkinson's disease. Glia, 2008, 56, 1215-1223. | 2.5 | 123 |
| 265 | Chaperone proteins identified from synthetic proteasome inhibitor-induced inclusions in PC12 cells by proteomic analysis. Acta Biochimica Et Biophysica Sinica, 2008, 40, 406-418. | 0.9 | 6 |
| 266 | The DISC locus in psychiatric illness. Molecular Psychiatry, 2008, 13, 36-64. | 4.1 | 554 |

| # | Article | IF | Citations |
|---|---|---|---|
| 267 | New insights into the pathology of Parkinsonâ€™s disease: does the peripheral autonomic system become central?. European Journal of Neurology, 2008, 15, 1-4. | 1.7 | 48 |
| 268 | The effect of Î±â€synuclein knockdown on MPP+ toxicity in models of human neurons. European Journal of Neuroscience, 2008, 28, 2459-2473. | 1.2 | 67 |
| 269 | Heterogeneous in vitro effects of doxorubicin on gene expression in primary human liposarcoma cultures. BMC Cancer, 2008, 8, 313. | 1.1 | 21 |
| 270 | Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmunity Reviews, 2008, 7, 501-507. | 2.5 | 56 |
| 271 | Genetic factors involved in the pathogenesis of Parkinson's disease. Brain Research Reviews, 2008, 58, 354-364. | 9.1 | 35 |
| 272 | Neuropathology of Parkinson's Disease. , 2008, , 35-48. | | 6 |
| 273 | Chapter 6 Molecular and Cellular Biology of Synucleins. International Review of Cell and Molecular Biology, 2008, 270, 225-317. | 1.6 | 90 |
| 274 | Î±-Synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: Lessons from viral transduction of knockout mice. Neuroscience Letters, 2008, 435, 24-29. | 1.0 | 91 |
| 275 | Melatonin inhibits amphetamine-induced increase in Î±-synuclein and decrease in phosphorylated tyrosine hydroxylase in SKâ€“Nâ€“SH cells. Neuroscience Letters, 2008, 436, 309-313. | 1.0 | 40 |
| 276 | Î±-synuclein and Parkinsonâ€™s disease: a proteomic view. Expert Review of Proteomics, 2008, 5, 239-248. | 1.3 | 31 |
| 277 | Differences between normal and alpha-synuclein overexpressing SH-SY5Y neuroblastoma cells after AÎ²(1-42) and NAC treatment. Brain Research Bulletin, 2008, 75, 648-654. | 1.4 | 12 |
| 278 | Phosphorylation of cysteine string protein on Serine 10 triggers 14-3-3 protein binding. Biochemical and Biophysical Research Communications, 2008, 377, 809-814. | 1.0 | 13 |
| 279 | Proteomics Analysis Identifies Phosphorylation-dependent Î±-Synuclein Protein Interactions. Molecular and Cellular Proteomics, 2008, 7, 2123-2137. | 2.5 | 157 |
| 280 | Phosphorylation at Ser-129 but Not the Phosphomimics S129E/D Inhibits the Fibrillation of Î±-Synuclein. Journal of Biological Chemistry, 2008, 283, 16895-16905. | 1.6 | 302 |
| 281 | α-Synuclein Misfolding and Neurodegenerative Diseases. Current Protein and Peptide Science, 2008, 9, 507-540. | 0.7 | 177 |
| 282 | Drug Targeting of Î±-Synuclein Oligomerization in Synucleinopathies. Perspectives in Medicinal Chemistry, 2008, 2, 1177391X0800200. | 4.6 | 3 |
| 283 | Neuroprotective and Neurotoxic Properties of Î±-Synuclein in Cell Culture Models of Dopaminergic Degeneration. , 2008, , 475-490. | | 0 |
| 284 | 14-3-3Î¶ Contributes to Tyrosine Hydroxylase Activity in MN9D Cells. Journal of Biological Chemistry, 2009, 284, 14011-14019. | 1.6 | 72 |

| # | Article | IF | Citations |
|---|---|---|---|
| 285 | Î±â€Synuclein contributes to GSKâ€3Î²â€catalyzed Tau phosphorylation in Parkinson's disease models. FASEB Journal, 2009, 23, 2820-2830. | 0.2 | 231 |
| 286 | The Therapeutic Potential of LRRK2 and Î±-Synuclein in Parkinson's Disease. Antioxidants and Redox Signaling, 2009, 11, 2167-2187. | 2.5 | 9 |
| 287 | Physiological and Pathological Role of Alpha-synuclein in Parkinsonâ€™s Disease Through Iron Mediated Oxidative Stress; The Role of a Putative Iron-responsive Element. International Journal of Molecular Sciences, 2009, 10, 1226-1260. | 1.8 | 75 |
| 288 | Desipramine Modulation of Î±-, Î³-Synuclein, and the Norepinephrine Transporter in an Animal Model of Depression. Neuropsychopharmacology, 2009, 34, 987-998. | 2.8 | 41 |
| 289 | The role of Î±-synuclein in brain lipid metabolism: a downstream impact on brain inflammatory response. Molecular and Cellular Biochemistry, 2009, 326, 55-66. | 1.4 | 69 |
| 290 | 2â€D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics, 2009, 9, 3368-3382. | 1.3 | 134 |
| 291 | Proteomic analysis of increased Parkin expression and its interactants provides evidence for a role in modulation of mitochondrial function. Proteomics, 2009, 9, 4284-4297. | 1.3 | 70 |
| 292 | Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease. Molecular Neurodegeneration, 2009, 4, 32. | 4.4 | 34 |
| 293 | Pre-fibrillar Î±-synuclein variants with impaired Î²-structure increase neurotoxicity in Parkinson's disease models. EMBO Journal, 2009, 28, 3256-3268. | 3.5 | 411 |
| 294 | Gating deficits in isolationâ€reared rats are correlated with alterations in protein expression in nucleus accumbens. Journal of Neurochemistry, 2009, 108, 611-620. | 2.1 | 20 |
| 295 | Molecular Mechanisms Underlying the Flavonoid-Induced Inhibition of Î±-Synuclein Fibrillation. Biochemistry, 2009, 48, 8206-8224. | 1.2 | 126 |
| 296 | Structural insights on physiological functions and pathological effects of Â±â€synuclein. FASEB Journal, 2009, 23, 329-340. | 0.2 | 129 |
| 297 | Molecular mechanisms of Î±-synuclein neurodegeneration. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 616-624. | 1.8 | 174 |
| 298 | Desipramine induced changes in the norepinephrine transporter, Î±- and Î³-synuclein in the hippocampus, amygdala and striatum. Neuroscience Letters, 2009, 467, 86-89. | 1.0 | 15 |
| 299 | Current and Future Therapeutic Strategies for Parkinsons Disease. Current Pharmaceutical Design, 2009, 15, 3968-3976. | 0.9 | 11 |
| 300 | Membrane Interactions of Oligomeric Alpha-Synuclein: Potential Role in Parkinsons Disease. Current Protein and Peptide Science, 2010, 11, 334-342. | 0.7 | 42 |
| 301 | 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochemical Journal, 2010, 430, 393-404. | 1.7 | 355 |
| 302 | Periphilin is a novel interactor of synphilin-1, a protein implicated in Parkinson's disease. Neurogenetics, 2010, 11, 203-215. | 0.7 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 303 | The regulatory role of Î±-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinsonâ€™s disease. Apoptosis: an International Journal on Programmed Cell Death, 2010, 15, 1312-1321. | 2.2 | 44 |
| 304 | Overexpression of Î±-Synuclein Down-Regulates BDNF Expression. Cellular and Molecular Neurobiology, 2010, 30, 939-946. | 1.7 | 54 |
| 305 | Proteomic characterization of an isolated fraction of synthetic proteasome inhibitor (PSI)-induced inclusions in PC12 cells might offer clues to aggresomes as a cellular defensive response against proteasome inhibition by PSI. BMC Neuroscience, 2010, 11, 95. | 0.8 | 7 |
| 306 | Mesencephalic and striatal protein profiles in mice over-expressing glucose-6-phosphate dehydrogenase in dopaminergic neurons. Journal of Proteomics, 2010, 73, 1747-1757. | 1.2 | 5 |
| 307 | 14-3-3 Proteins and regulation of cytoskeleton. Biochemistry (Moscow), 2010, 75, 1528-1546. | 0.7 | 67 |
| 308 | DNA induced folding/fibrillation of alpha-synuclein: new insights in Parkinson's disease. Frontiers in Bioscience - Landmark, 2010, 15, 418. | 3.0 | 41 |
| 309 | Serine 129 Phosphorylation Reduces the Ability of Î±-Synuclein to Regulate Tyrosine Hydroxylase and Protein Phosphatase 2A in Vitro and in Vivo. Journal of Biological Chemistry, 2010, 285, 17648-17661. | 1.6 | 105 |
| 310 | A Biochemical and Functional Protein Complex Involving Dopamine Synthesis and Transport into Synaptic Vesicles. Journal of Biological Chemistry, 2010, 285, 1957-1966. | 1.6 | 106 |
| 311 | Regulation of Weibel-Palade Body Exocytosis by Î±-Synuclein in Endothelial Cells. Journal of Biological Chemistry, 2010, 285, 21416-21425. | 1.6 | 34 |
| 312 | LRRK2 and the Stress Response: Interaction with MKKs and JNK-Interacting Proteins. Neurodegenerative Diseases, 2010, 7, 68-75. | 0.8 | 57 |
| 313 | Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease. Cell Death and Disease, 2010, 1, e2-e2. | 2.7 | 120 |
| 314 | The Role of Phosphorylation in Synucleinopathies: Focus on Parkinsons Disease. CNS and Neurological Disorders - Drug Targets, 2010, 9, 471-481. | 0.8 | 43 |
| 315 | Role of post-translational modifications in modulating the structure, function and toxicity of Î±-synuclein. Progress in Brain Research, 2010, 183, 115-145. | 0.9 | 283 |
| 316 | Î±Î²Î³-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19573-19578. | 3.3 | 261 |
| 317 | A Querying Method with Feedback Mechanism for Protein Interaction Network. , 2011, , . | | 5 |
| 320 | Blood-Based Protein Biomarkers for Diagnosis and Classification of Neurodegenerative Diseases. Molecular Diagnosis and Therapy, 2011, 15, 83-102. | 1.6 | 25 |
| 321 | Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism. Pharmacological Research, 2011, 63, 439-444. | 3.1 | 125 |
| 322 | Dopamine-depletion and increased Î±-synuclein load induce degeneration of cortical cholinergic fibers in mice. Journal of the Neurological Sciences, 2011, 310, 90-95. | 0.3 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 323 | Flexible Nets of Malleable Guardians: Intrinsically Disordered Chaperones in Neurodegenerative Diseases. Chemical Reviews, 2011, 111, 1134-1166. | 23.0 | 65 |
| 324 | Tyrosine hydroxylase and regulation of dopamine synthesis. Archives of Biochemistry and Biophysics, 2011, 508, 1-12. | 1.4 | 720 |
| 325 | Proteomic characterization of Jurkat T leukemic cells after dopamine stimulation: A model of circulating dopamine-sensitive cells. Biochimie, 2011, 93, 892-898. | 1.3 | 5 |
| 326 | Heat Shock Protein 70 Prevents both Tau Aggregation and the Inhibitory Effects of Preexisting Tau Aggregates on Fast Axonal Transport. Biochemistry, 2011, 50, 10300-10310. | 1.2 | 106 |
| 327 | Melatonin attenuates the amphetamine-induced decrease in vesicular monoamine transporter-2 expression in postnatal rat striatum. Neuroscience Letters, 2011, 488, 154-157. | 1.0 | 10 |
| 328 | Macroautophagy and the proteasome are differently involved in the degradation of alpha-synuclein wild type and mutated A30P in an in vitro inducible model (PC12/TetOn). Neuroscience, 2011, 195, 128-137. | 1.1 | 26 |
| 330 | 14-3-3 proteins in neurodegeneration. Seminars in Cell and Developmental Biology, 2011, 22, 696-704. | 2.3 | 85 |
| 331 | Synuclein modulation of monoamine transporters. FEBS Letters, 2011, 585, 1001-1006. | 1.3 | 64 |
| 333 | Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD. Parkinson's Disease, 2011, 2011, 1-20. | 0.6 | 62 |
| 334 | LRRK2 mutations, regulation and 14â€“3â€“3 protein interaction: implications for Parkinsonâ€™s disease. Future Neurology, 2011, 6, 5-8. | 0.9 | 0 |
| 335 | Protection of dichlorvos induced oxidative stress and nigrostriatal neuronal death by chronic Coenzyme Q10 pretreatment. Toxicology and Applied Pharmacology, 2011, 256, 73-82. | 1.3 | 20 |
| 336 | Alpha-synuclein aggregation is involved in the toxicity induced by ferric iron to SK-N-SH neuroblastoma cells. Journal of Neural Transmission, 2011, 118, 397-406. | 1.4 | 27 |
| 337 | Synphilin-1 inhibits alpha-synuclein degradation by the proteasome. Cellular and Molecular Life Sciences, 2011, 68, 2643-2654. | 2.4 | 31 |
| 338 | Interference of alpha-synuclein with cAMP/PKA-dependent CREB signaling for tyrosine hydroxylase gene expression in SK-N-BE(2)C cells. Archives of Pharmacal Research, 2011, 34, 837-845. | 2.7 | 21 |
| 339 | Structures of segments of Î±â€synuclein fused to maltoseâ€binding protein suggest intermediate states during amyloid formation. Protein Science, 2011, 20, 996-1004. | 3.1 | 32 |
| 340 | Intrinsically disordered proteins may escape unwanted interactions via functional misfolding. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2011, 1814, 693-712. | 1.1 | 56 |
| 341 | Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neuroscience and Biobehavioral Reviews, 2011, 35, 848-870. | 2.9 | 147 |
| 342 | Familial Parkinson's Disease Mutant E46KÎ±-Synuclein Localizes to Membranous Structures, Forms Aggregates, and Induces Toxicity in Yeast Models. ISRN Neurology, 2011, 2011, 1-14. | 1.5 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 343 | Î±-Synuclein Negatively Regulates Protein Kinase CÎ´ Expression to Suppress Apoptosis in Dopaminergic Neurons by Reducing p300 Histone Acetyltransferase Activity. Journal of Neuroscience, 2011, 31, 2035-2051. | 1.7 | 136 |
| 344 | Parkinsonian Neurotoxin 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and Î±-Synuclein Mutations Promote Tau Protein Phosphorylation at Ser262 and Destabilize Microtubule Cytoskeleton in Vitro. Journal of Biological Chemistry, 2011, 286, 5055-5068. | 1.6 | 72 |
| 345 | Î±-Synuclein binds the K<sub>ATP</sub> channel at insulin-secretory granules and inhibits insulin secretion. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E276-E286. | 1.8 | 71 |
| 346 | NMNAT suppresses Tau-induced neurodegeneration by promoting clearance of hyperphosphorylated Tau oligomers in a Drosophila model of tauopathy. Human Molecular Genetics, 2012, 21, 237-250. | 1.4 | 97 |
| 347 | Î±-synuclein, LRRK2 and their interplay in Parkinsonâ€™s disease. Future Neurology, 2012, 7, 145-153. | 0.9 | 39 |
| 348 | Î±-Synuclein misfolding and Parkinson's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 261-285. | 1.8 | 526 |
| 349 | Â-Synuclein in Parkinson's Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a009399-a009399. | 2.9 | 958 |
| 350 | Loss of Functional Alpha-Synuclein: A Toxic Event in Parkinson's Disease?. Journal of Parkinson's Disease, 2012, 2, 249-267. | 1.5 | 72 |
| 351 | The chaperone activity of Î±â€synuclein: Utilizing deletion mutants to map its interaction with target proteins. Proteins: Structure, Function and Bioinformatics, 2012, 80, 1316-1325. | 1.5 | 26 |
| 352 | Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease. Brain Research, 2012, 1432, 95-113. | 1.1 | 39 |
| 353 | Structureâ€oriented review of 14â€3â€3 protein isoforms in geriatric neuroscience. Geriatrics and Gerontology International, 2012, 12, 586-599. | 0.7 | 9 |
| 354 | A53T-alpha-synuclein-overexpression in the mouse nigrostriatal pathway leads to early increase of 14-3-3 epsilon and late increase of GFAP. Journal of Neural Transmission, 2012, 119, 297-312. | 1.4 | 30 |
| 355 | Î±-Synuclein Overexpression Represses 14-3-3Î¸ Transcription. Journal of Molecular Neuroscience, 2013, 51, 1000-1009. | 1.1 | 19 |
| 356 | Î±-Synuclein Protects Neurons from Apoptosis Downstream of Free-Radical Production Through Modulation of the MAPK Signalling Pathway. Neurotoxicity Research, 2013, 23, 358-369. | 1.3 | 28 |
| 357 | Basal Ganglia Disorders. , 2013, , 1-39. | | 0 |
| 358 | 14-3-3 Proteins in the Regulation of Rotenone-Induced Neurotoxicity Might be via Its Isoform 14-3-3Epsilonâ€™s Involvement in Autophagy. Cellular and Molecular Neurobiology, 2013, 33, 1109-1121. | 1.7 | 9 |
| 359 | Evolutionary aspects of the synuclein super-family and sub-families based on large-scale phylogenetic and group-discrimination analysis. Biochemical and Biophysical Research Communications, 2013, 441, 308-317. | 1.0 | 18 |
| 360 | 14-3-3 targets chaperone-associated misfolded proteins to aggresomes. Journal of Cell Science, 2013, 126, 4173-86. | 1.2 | 87 |

| # | Article | IF | Citations |
|---|---|---|---|
| 361 | Kinaseâ€“Kinase Interaction and Modulation of Tau Phosphorylation. International Review of Cell and Molecular Biology, 2013, 300, 121-160. | 1.6 | 33 |
| 362 | Valproic acid ameliorates C. elegans dopaminergic neurodegeneration with implications for ERK-MAPK signaling. Neuroscience Letters, 2013, 541, 116-119. | 1.0 | 19 |
| 363 | The role of Î±-synuclein in the pathophysiology of alcoholism. Neurochemistry International, 2013, 63, 154-162. | 1.9 | 16 |
| 364 | Molecular Chaperones, Alpha-Synuclein, and Neurodegeneration. Molecular Neurobiology, 2013, 47, 552-560. | 1.9 | 47 |
| 365 | Stem Cells in the Adult Brain. , 2013, , 699-705. | | 1 |
| 366 | Î±-Synuclein and Î²-synuclein enhance secretion protein production in baculovirus expression vector system. Applied Microbiology and Biotechnology, 2013, 97, 3875-3884. | 1.7 | 2 |
| 367 | Limelight on Alpha-Synuclein: Pathological and Mechanistic Implications in Neurodegeneration. Journal of Parkinson's Disease, 2013, 3, 415-459. | 1.5 | 68 |
| 368 | Neuroprotective Function of 14-3-3 Proteins in Neurodegeneration. BioMed Research International, 2013, 2013, 1-11. | 0.9 | 75 |
| 369 | TFEB-mediated autophagy rescues midbrain dopamine neurons from Î±-synuclein toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1817-26. | 3.3 | 600 |
| 370 | Alpha-Synuclein Function and Dysfunction on Cellular Membranes. Experimental Neurobiology, 2014, 23, 292-313. | 0.7 | 179 |
| 371 | The triple power of DÂ³: Protein intrinsic disorder in degenerative diseases. Frontiers in Bioscience - Landmark, 2014, 19, 181. | 3.0 | 78 |
| 372 | Alpha-synuclein and tau: teammates in neurodegeneration?. Molecular Neurodegeneration, 2014, 9, 43. | 4.4 | 216 |
| 373 | A calcineurin- and NFAT-dependent pathway is involved in Â-synuclein-induced degeneration of midbrain dopaminergic neurons. Human Molecular Genetics, 2014, 23, 6567-6574. | 1.4 | 57 |
| 374 | Potential of caveolae in the therapy of cardiovascular and neurological diseases. Frontiers in Physiology, 2014, 5, 370. | 1.3 | 17 |
| 375 | Intraâ€axonal protein aggregation in the peripheral nervous system. Journal of the Peripheral Nervous System, 2014, 19, 44-49. | 1.4 | 15 |
| 376 | The Crystal Structure of Giardia duodenalis 14-3-3 in the Apo Form: When Protein Post-Translational Modifications Make the Difference. PLoS ONE, 2014, 9, e92902. | 1.1 | 12 |
| 377 | Association of heat-shock proteins in various neurodegenerative disorders: is it a master key to open the therapeutic door?. Molecular and Cellular Biochemistry, 2014, 386, 45-61. | 1.4 | 86 |
| 378 | Targeting heat shock proteins to modulate Î±-synuclein toxicity. Therapeutic Advances in Neurological Disorders, 2014, 7, 33-51. | 1.5 | 53 |

| # | Article | IF | Citations |
|---|---|---|---|
| 379 | Linking alpha-synuclein properties with oxidation: a hypothesis on a mechanism underling cellular aggregation. Journal of Bioenergetics and Biomembranes, 2014, 46, 93-98. | 1.0 | 15 |
| 380 | The chaperone-like protein 14-3-3Î· interacts with human Î±-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing Î±-synuclein cellular toxicity. Human Molecular Genetics, 2014, 23, 5615-5629. | 1.4 | 56 |
| 381 | The Neurobiology of LRRK2 and its Role in the Pathogenesis of Parkinsonâ€™s Disease. Neurochemical Research, 2014, 39, 576-592. | 1.6 | 61 |
| 382 | Use of CSF Î±-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders. International Psychogeriatrics, 2015, 27, 1429-1438. | 0.6 | 30 |
| 383 | Age-Related Changes of 14-3-3 IsoformsÂinÂMidbrain of A53T-SNCA Overexpressing Mice. Journal of Parkinson's Disease, 2015, 5, 595-604. | 1.5 | 5 |
| 384 | The Synaptic Function of Î±-Synuclein. Journal of Parkinson's Disease, 2015, 5, 699-713. | 1.5 | 421 |
| 385 | Neuronal response in Alzheimerâ€™s and Parkinsonâ€™s disease: the effect of toxic proteins on intracellular pathways. BMC Neuroscience, 2015, 16, 69. | 0.8 | 61 |
| 386 | A new role for Î±â€synuclein in Parkinson's disease: Alteration of ERâ€“mitochondrial communication. Movement Disorders, 2015, 30, 1026-1033. | 2.2 | 59 |
| 387 | Olfactory Dysfunction and Neurotransmitter Disturbance in Olfactory Bulb of Transgenic Mice Expressing Human A53T Mutant Î±-Synuclein. PLoS ONE, 2015, 10, e0119928. | 1.1 | 57 |
| 388 | Complexin-1 and Foxp1 Expression Changes Are Novel Brain Effects of Alpha-Synuclein Pathology. Molecular Neurobiology, 2015, 52, 57-63. | 1.9 | 20 |
| 389 | Proteomics Approach to Identify Biomarkers in Neurodegenerative Diseases. International Review of Neurobiology, 2015, 121, 59-86. | 0.9 | 9 |
| 390 | Biomarkers of Parkinsonâ€™s Disease. Biomarkers in Disease, 2015, , 1009-1030. | 0.0 | 0 |
| 391 | Increased 14-3-3 phosphorylation observed in Parkinson's disease reduces neuroprotective potential of 14-3-3 proteins. Neurobiology of Disease, 2015, 79, 1-13. | 2.1 | 34 |
| 392 | Intracellular Dynamics of Synucleins. International Review of Cell and Molecular Biology, 2015, 320, 103-169. | 1.6 | 66 |
| 393 | 14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3Î¸ overexpression promotes recovery in the MPTP mouse model of Parkinsonâ€™s disease. Neuroscience, 2015, 307, 73-82. | 1.1 | 20 |
| 394 | Potential Role of Epigenetic Mechanism in Manganese Induced Neurotoxicity. BioMed Research International, 2016, 2016, 1-18. | 0.9 | 40 |
| 395 | Parkinsonâ€™s Disease and Cognitive Impairment. Parkinson's Disease, 2016, 2016, 1-8. | 0.6 | 50 |
| 396 | Brain Disorders Due to Lysosomal Dysfunction. Annual Review of Neuroscience, 2016, 39, 277-295. | 5.0 | 129 |

| # | Article | IF | Citations |
|---|---|---|---|
| 397 | The contribution of alpha synuclein to neuronal survival and function â€“ Implications for Parkinson's disease. Journal of Neurochemistry, 2016, 137, 331-359. | 2.1 | 186 |
| 398 | Mitochondrial Dysfunction in Neurodegenerative Disorders. , 2016, , . | | 3 |
| 399 | The Deleterious Duo of Neurodegeneration: Lysosomes and Mitochondria. , 2016, , 279-300. | | 2 |
| 400 | TFEB and TFE3: Linking Lysosomes to Cellular Adaptation to Stress. Annual Review of Cell and Developmental Biology, 2016, 32, 255-278. | 4.0 | 308 |
| 401 | Dynamic structural flexibility of Î±-synuclein. Neurobiology of Disease, 2016, 88, 66-74. | 2.1 | 65 |
| 402 | What lysosomes actually tell us about Parkinsonâ€™s disease?. Ageing Research Reviews, 2016, 32, 140-149. | 5.0 | 19 |
| 403 | Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. Progress in Neurobiology, 2017, 155, 171-193. | 2.8 | 137 |
| 404 | FLZ Attenuates Î±-Synuclein-Induced Neurotoxicity by Activating Heat Shock Protein 70. Molecular Neurobiology, 2017, 54, 349-361. | 1.9 | 20 |
| 405 | Alpha-synuclein modulates dopamine neurotransmission. Journal of Chemical Neuroanatomy, 2017, 83-84, 41-49. | 1.0 | 46 |
| 406 | Dysregulation of 14â€3â€3 proteins in neurodegenerative diseases with Lewy body or Alzheimer pathology. Annals of Clinical and Translational Neurology, 2017, 4, 466-477. | 1.7 | 28 |
| 407 | DJ-1, a Parkinson's disease related protein, aggregates under denaturing conditions and co-aggregates with Î±-synuclein through hydrophobic interaction. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1759-1769. | 1.1 | 15 |
| 408 | Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinsonâ€™s disease. An integrated strategy for management. Ageing Research Reviews, 2017, 40, 149-167. | 5.0 | 47 |
| 409 | Post translational changes to Î±-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinsonâ€™s disease. Molecular Neurodegeneration, 2017, 12, 45. | 4.4 | 61 |
| 410 | Nuclear Accumulation of Histone Deacetylase 4 (HDAC4) Exerts Neurotoxicity in Models of Parkinsonâ€™s Disease. Molecular Neurobiology, 2017, 54, 6970-6983. | 1.9 | 48 |
| 411 | Molecular Biology of Dementia with Lewy Bodies. , 2017, , 41-55. | | 1 |
| 413 | The Role of Interleukin-18, Oxidative Stress and Metabolic Syndrome in Alzheimerâ€™s Disease. Journal of Clinical Medicine, 2017, 6, 55. | 1.0 | 40 |
| 414 | Genomic DNA levels of mutant alpha-synuclein correlate with non-motor symptoms in an A53T Parkinson's disease mouse model. Neurochemistry International, 2018, 114, 71-79. | 1.9 | 27 |
| 415 | LRRK2 Phosphorylation: Behind the Scenes. Neuroscientist, 2018, 24, 486-500. | 2.6 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 416 | Alpha-synuclein mitochondrial interaction leads to irreversible translocation and complex I impairment. Archives of Biochemistry and Biophysics, 2018, 651, 1-12. | 1.4 | 45 |
| 417 | 14-3-3 protein sigma isoform co-localizes with phosphorylated Î±-synuclein in Lewy bodies and Lewy neurites in patients with Lewy body disease. Neuroscience Letters, 2018, 674, 171-175. | 1.0 | 11 |
| 418 | Cell Biology and Pathophysiology of Î±-Synuclein. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a024091. | 2.9 | 353 |
| 419 | Alpha-Synuclein Suppresses Retinoic Acid-Induced Neuronal Differentiation by Targeting the Glycogen Synthase Kinase-3Î²/Î²-Catenin Signaling Pathway. Molecular Neurobiology, 2018, 55, 1607-1619. | 1.9 | 14 |
| 420 | Downregulation of 14-3-3 Proteins in a Kainic Acid-Induced Neurotoxicity Model. Molecular Neurobiology, 2018, 55, 122-129. | 1.9 | 20 |
| 421 | East Indian sandalwood (Santalum albumÂL.) oil confers neuroprotection and geroprotection inCaenorhabditis elegans viaactivating SKN-1/Nrf2 signaling pathway. RSC Advances, 2018, 8, 33753-33774. | 1.7 | 36 |
| 422 | Network-based Analysis Approach to Prioritize GWAS of CSF in the ADNI Cohort. , 2018, , . | | 1 |
| 423 | Could Î±-Synuclein Modulation of Insulin and Dopamine Identify a Novel Link Between Parkinsonâ€™s Disease and Diabetes as Well as Potential Therapies?. Frontiers in Molecular Neuroscience, 2018, 11, 465. | 1.4 | 11 |
| 424 | Pathogenic Feed-Forward Mechanisms in Alzheimerâ€™s and Parkinsonâ€™s Disease Converge on GSK-3. Brain Plasticity, 2018, 4, 151-167. | 1.9 | 19 |
| 425 | Comparative Analysis of the Conformation, Aggregation, Interaction, and Fibril Morphologies of Human Î±-, Î²-, and Î³-Synuclein Proteins. Biochemistry, 2018, 57, 3830-3848. | 1.2 | 27 |
| 426 | Structure, Function, Involvement in Diseases and Targeting of 14-3-3 Proteins: An Update. Current Medicinal Chemistry, 2018, 25, 5-21. | 1.2 | 56 |
| 427 | Methionine sulfoxide reductase A (MsrA) mediates the ubiquitination of 14-3-3 protein isotypes in brain. Free Radical Biology and Medicine, 2018, 129, 600-607. | 1.3 | 10 |
| 428 | 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic Î±-Synuclein. Journal of Neuroscience, 2018, 38, 8211-8232. | 1.7 | 48 |
| 429 | TFEB dysregulation as a driver of autophagy dysfunction in neurodegenerative disease: Molecular mechanisms, cellular processes, and emerging therapeutic opportunities. Neurobiology of Disease, 2019, 122, 83-93. | 2.1 | 135 |
| 430 | 14-3-3 Proteins Are on the Crossroads of Cancer, Aging, and Age-Related Neurodegenerative Disease. International Journal of Molecular Sciences, 2019, 20, 3518. | 1.8 | 80 |
| 431 | Acrolein-mediated alpha-synuclein pathology involvement in the early post-injury pathogenesis of mild blast-induced Parkinsonian neurodegeneration. Molecular and Cellular Neurosciences, 2019, 98, 140-154. | 1.0 | 21 |
| 432 | Axonal pathology in hPSC-based models of Parkinsonâ€™s disease results from loss of Nrf2 transcriptional activity at the Map1b gene locus. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 14280-14289. | 3.3 | 30 |
| 433 | The role of lipids in Î±-synuclein misfolding and neurotoxicity. Journal of Biological Chemistry, 2019, 294, 9016-9028. | 1.6 | 55 |

| # | Article | IF | Citations |
|---|---|---|---|
| 434 | 14-3-3 gene family in spotted sea bass (Lateolabrax maculatus): Genome-wide identification, phylogenetic analysis and expression profiles after salinity stress. Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology, 2019, 235, 1-11. | 0.8 | 10 |
| 435 | In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategies. Journal of Neurochemistry, 2019, 150, 535-565. | 2.1 | 33 |
| 436 | Prion Efficiently Replicates in Î±-Synuclein Knockout Mice. Molecular Neurobiology, 2019, 56, 7448-7457. | 1.9 | 5 |
| 437 | Construction of Parkinson's disease marker-based weighted protein-protein interaction network for prioritization of co-expressed genes. Gene, 2019, 697, 67-77. | 1.0 | 17 |
| 439 | Can 14-3-3 proteins serve as therapeutic targets for the treatment of metabolic diseases?. Pharmacological Research, 2019, 139, 199-206. | 3.1 | 31 |
| 440 | Living in Promiscuity: The Multiple Partners of Alpha-Synuclein at the Synapse in Physiology and Pathology. International Journal of Molecular Sciences, 2019, 20, 141. | 1.8 | 52 |
| 441 | Increased Cholinergic Response in Î±-Synuclein Transgenic Mice (h-Î±-synL62). ACS Chemical Neuroscience, 2019, 10, 1915-1922. | 1.7 | 11 |
| 442 | The interaction of Î±-synuclein and Tau: A molecular conspiracy in neurodegeneration?. Seminars in Cell and Developmental Biology, 2020, 99, 55-64. | 2.3 | 35 |
| 443 | Utility of totally implantable venous access ports in patients with breast cancer. Breast Journal, 2020, 26, 333-334. | 0.4 | 3 |
| 444 | Controlled synthesis of nanostructured glassy and crystalline high entropy alloy films. Nanotechnology, 2020, 31, 045601. | 1.3 | 2 |
| 445 | Loss of fragile X mental retardation protein precedes Lewy pathology in Parkinsonâ€™s disease. Acta Neuropathologica, 2020, 139, 319-345. | 3.9 | 17 |
| 446 | LRRK2 and Î±-Synuclein: Distinct or Synergistic Players in Parkinsonâ€™s Disease?. Frontiers in Neuroscience, 2020, 14, 577. | 1.4 | 49 |
| 447 | iPSC modeling of young-onset Parkinsonâ€™s disease reveals a molecular signature of disease and novel therapeutic candidates. Nature Medicine, 2020, 26, 289-299. | 15.2 | 102 |
| 448 | Immunotherapies for Aging-Related Neurodegenerative Diseasesâ€”Emerging Perspectives and New Targets. Neurotherapeutics, 2020, 17, 935-954. | 2.1 | 40 |
| 449 | Advances in modelling alpha-synuclein-induced Parkinsonâ€™s diseases in rodents: Virus-based models versus inoculation of exogenous preformed toxic species. Journal of Neuroscience Methods, 2020, 338, 108685. | 1.3 | 16 |
| 450 | Neurons and Glia Interplay in Î±-Synucleinopathies. International Journal of Molecular Sciences, 2021, 22, 4994. | 1.8 | 28 |
| 451 | Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies. Redox Biology, 2021, 41, 101896. | 3.9 | 75 |
| 452 | Harnessing the immune system for the treatment of Parkinsonâ€™s disease. Brain Research, 2021, 1758, 147308. | 1.1 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 453 | Alpha-Synuclein Post-translational Modifications: Implications for Pathogenesis of Lewy Body Disorders. Frontiers in Aging Neuroscience, 2021, 13, 690293. | 1.7 | 32 |
| 454 | Roles for Î±-Synuclein in Gene Expression. Genes, 2021, 12, 1166. | 1.0 | 16 |
| 455 | Effects of Alpha-Synuclein Targeted Antisense Oligonucleotides on Lewy Body-Like Pathology and Behavioral Disturbances Induced by Injections of Pre-Formed Fibrils in the Mouse Motor Cortex. Journal of Parkinson's Disease, 2021, 11, 1091-1115. | 1.5 | 10 |
| 456 | Prediction and verification of the AD-FTLD common pathomechanism based on dynamic molecular network analysis. Communications Biology, 2021, 4, 961. | 2.0 | 2 |
| 457 | Synaptic tau: A pathological or physiological phenomenon?. Acta Neuropathologica Communications, 2021, 9, 149. | 2.4 | 30 |
| 458 | Pathways to Parkinsonâ€™s disease: a spotlight on 14-3-3 proteins. Npj Parkinson's Disease, 2021, 7, 85. | 2.5 | 20 |
| 459 | 14-3-3Î¶ and 14-3-3Îµ are involved in innate immune responses in Pacific abalone (Haliotis discus hannai). Developmental and Comparative Immunology, 2021, 124, 104176. | 1.0 | 4 |
| 460 | Similarity of the non-amyloid-Î² component and C-terminal tail of monomeric and tetrameric alpha-synuclein with 14-3-3 sigma. Computational and Structural Biotechnology Journal, 2021, 19, 5348-5359. | 1.9 | 7 |
| 461 | Mouse Models of Î±-Synucleinopathy and Lewy Pathology. Advances in Experimental Medicine and Biology, 2001, 487, 147-167. | 0.8 | 8 |
| 462 | Î±-Synuclein modulates tau spreading in mouse brains. Journal of Experimental Medicine, 2021, 218, . | 4.2 | 49 |
| 463 | Direct binding and functional coupling of Î±â€synuclein to the dopamine transporters accelerate dopamineâ€induced apoptosis. FASEB Journal, 2001, 15, 916-926. | 0.2 | 60 |
| 464 | Regulation of Â-Synuclein Expression: Implications for Parkinson's Disease. Cold Spring Harbor Symposia on Quantitative Biology, 2003, 68, 409-416. | 2.0 | 11 |
| 465 | DEGAS: De Novo Discovery of Dysregulated Pathways in Human Diseases. PLoS ONE, 2010, 5, e13367. | 1.1 | 113 |
| 466 | A Synopsis on the Role of Tyrosine Hydroxylase in Parkinsonâ€™s Disease. CNS and Neurological Disorders - Drug Targets, 2012, 11, 395-409. | 0.8 | 111 |
| 467 | Alpha-synuclein structure, functions, and interactions. Journal of Research in Medical Sciences, 2016, 21, 29. | 0.4 | 180 |
| 468 | Emerging roles of 14-3-3Î³ in the brain disorder. BMB Reports, 2020, 53, 500-511. | 1.1 | 20 |
| 469 | The Amyloid Fibril-Forming Î²-Sheet Regions of Amyloid Î² and Î±-Synuclein Preferentially Interact with the Molecular Chaperone 14-3-3Î¶. Molecules, 2021, 26, 6120. | 1.7 | 9 |
| 470 | Molecular Biology of Î±-Synuclein. Advances in Behavioral Biology, 2002, , 497-508. | 0.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 474 | Dissecting the Biochemical Pathways Mediated by Genes Implicated in Parkinsonâ€™s Disease: Induction of DJ-1 Expression in A30P Î±-Synuclein Mice. , 2008, , 97-112. | | 0 |
| 475 | Small Heat Shock Proteins and the Cytoskeleton. , 2009, , 13-24. | | 3 |
| 477 | Targeting Î±-Synuclein-Related Synaptic Pathology: Novel Clues for Parkinsonâ€™s Disease Therapy. , 0, , . | | 0 |
| 479 | Biomarkers of Parkinsonâ€™s Disease. , 2014, , 1-18. | | 0 |
| 481 | Cell Biology of Î±-Synuclein: Implications in Parkinsonâ€™s Disease and Other Lewy Body Diseases. , 0, , 111-124. | | 0 |
| 483 | Multiple system atrophy: cellular and molecular pathology. Journal of Clinical Pathology, 2001, 54, 419-26. | 2.1 | 39 |
| 484 | Alpha-synuclein overexpression promotes aggregation of mutant huntingtin. Biochemical Journal, 2000, 346 Pt 3, 577-81. | 1.7 | 33 |
| 485 | Drug Targeting of alpha-Synuclein Oligomerization in Synucleinopathies. Perspectives in Medicinal Chemistry, 2008, 2, 41-9. | 4.6 | 4 |
| 487 | 14-3-3 proteins in neurological disorders. International Journal of Biochemistry and Molecular Biology, 2012, 3, 152-64. | 0.1 | 88 |
| 489 | Prospective of SNCA in nervous system diseases. , 2017, 3, 10-16. | | 0 |
| 490 | Fishing for synucleinopathy models. Fisheries and Aquatic Sciences, 2022, 25, 117-139. | 0.3 | 0 |
| 491 | Autophagy system as a potential therapeutic target for neurodegenerative diseases. Neurochemistry International, 2022, 155, 105308. | 1.9 | 11 |
| 493 | Alpha-synuclein: between synaptic function and dysfunction. Histology and Histopathology, 2003, 18, 1257-66. | 0.5 | 22 |
| 494 | 14-3-3Î¸ Does Not Protect against Behavioral or Pathological Deficits in Alzheimerâ€™s Disease Mouse Models. ENeuro, 2022, 9, ENEURO.0368-21.2022. | 0.9 | 2 |
| 495 | Autophagy and autophagyâ€related molecules in neurodegenerative diseases. Animal Models and Experimental Medicine, 2023, 6, 10-17. | 1.3 | 6 |
| 496 | Structural insights into the functional roles of 14-3-3 proteins. Frontiers in Molecular Biosciences, 0, 9, . | 1.6 | 23 |
| 497 | HtrA2 regulates Î±-Synuclein-mediated mitochondrial reactive oxygen species production in the mitochondria of microglia. Biochemical and Biophysical Research Communications, 2023, 638, 84-93. | 1.0 | 4 |
| 498 | Early Diagnosis of Parkinsonâ€™s Disease: Utility of Animal Models. , 0, , . | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 499 | Animal Models and the Pathogenesis of Parkinson's Disease. , 2011, , 113-161. | | 0 |